The Director, Quality Control provides strategic and operational leadership for all Quality Control (QC) activities supporting drug substance (DS) and dug product (DP) manufacturing at the site. This role is accountable for ensuing the generation of accurate, reliable, and compliant analytical data to support product release, stability, and lifecycle management in accordance with global GMP requirements.
The Director QC oversees all QC functions, including analytical, microbiological, and environmental monitoring programs, and ensures alignment with the overall control strategy. This role ensures inspection readiness data integrity, and continuous improvement of QC systems and processes. As a member of the site Quality Leadership Team, the Director partners cross-functionally with Manufacturing m QA, MSAT, AS&T, and Regulatory to support clinical and commercial manufacturing while advancing quality culture and operational excellence.
POSITION RESPONSIBILITIES
Provide strategic leadership and oversight of all QC activities supporting DS and DP manufacturing, including release testing, stability programs, and in-process testing.
Partner with AS&T to ensure the robustness and lifecycle management of the analytical control strategy including method qualification, validation, transfer, and performance monitoring.
Oversee analytical, microbiological, and environmental monitoring programs, ensuring compliance with GMP requirements and site contamination control strategy
Ensure data integrity, accuracy, and reliability of all QC data in accordance with regulatory expectations.
Establish and maintain inspection readiness, including hosting regulatory inspections and responding to health authority inquiries.
Drive timely and thorough investigations of OOS, OOT, and atypical results, ensuring appropriate root cause identification and effective CAPA implementation.
Ensure appropriate specifications, test methods, and acceptance criteria are established and maintained throughout the product lifecycle.
Oversee QC laboratory operations including resource planning, capacity management, and organizational capability development
Partner cross-functionally with Manufacturing, QA, MSAT, AS&T, and Regulatory Affairs to support batch release, process improvements, and regulatory submissions.
Lead continuous improvement initiatives to enhance laboratory efficiency, compliance, and right-first-time performance.
Develop and monitor QC performance metrics, identifying trends and driving actions to improve performance and compliance.
Build and develop a high performing QC organization, fostering a strong quality culture and technical excellence.
Participates in business sub-teams as a Subject Matter Expert (SME) to provide input on timeliness and to address analytical/microbiological related issues
Other responsibilities and duties as the company may from time-to-time assign
EDUCATION AND EXPERIENCE
TECHNICAL SKILLS / CORE COMPETENCIES

Cellectis is a global clinical-stage biopharmaceutical company. Pioneers and innovators in our field, our mission is to develop innovative treatments for patients with unmet medical needs.
With 25 years of expertise, we have the best-in-class gene editing platform focusing on immuno-oncology, and gene therapy. Through our efficient and precise TALEN® technology, we create allogeneic CAR-T cells capable of recognizing and combating cancer cells.
Today, our two* clinical programs target patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and non-Hodgkin lymphoma (NHL).
We are fully integrated and a leader in end-to-end gene editing, allogeneic CAR T-cell companies. With our in-house manufacturing, we control our gene and cell therapy process from start to finish with starting materials produced in Paris (France) and CAR-T therapy products created in Raleigh, NC.
We also have several ongoing strong collaborations, based on our TALEN® technology, with leading cell & gene therapy companies, including our recent partnership with AstraZeneca, to develop new product candidates in oncology, immunology, and treatment of rare diseases.
At Cellectis, we are committed to a cure.
Cellectis headquarters are in Paris, France, with additional locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).
To find out more about us, visit our website: www.cellectis.com. To learn more about our community guidelines, visit: http://www.cellectis.com/en/social-media-guidelines/
Follow our other social media account on X.
(*) On November 4, 2024, Cellectis decided to focus its current development efforts on the BALLI-01 and NATHALI-01 studies and therefore to deprioritize the development of UCART123.
TALEN® is a registered trademark owned by the Cellectis Group.